<DOC>
	<DOCNO>NCT00995085</DOCNO>
	<brief_summary>This clinical study design evaluate safety tolerability single oral administration Metadoxine slow release formulation subject diagnose ADHD . Study also assess cognitive effect drug administration .</brief_summary>
	<brief_title>Efficacy Study Metadoxine SR Formulation Attention Deficit Hyperactivity Disorder ( ADHD ) Subjects</brief_title>
	<detailed_description>Primary outcome measure safety tolerability study drug single dosing . Additional outcome include commission error rate TOVA test . The result measure standard score % compare value normal population . Exploratory outcome measure include : 1 . TOVA measure like response time , variability , omission etc . 2 . Subtests Wechsler : digit memory , digit-number sign etc</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>age 1845 diagnose ADHD PDD patient head injured patient patient suffer heart , lung , liver , kidney , intestinal , endocrine neurological disease patient sensitive vitamin B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>ADHD</keyword>
	<keyword>ADD</keyword>
	<keyword>TOVA</keyword>
	<keyword>METADOXINE</keyword>
</DOC>